Episode 4. Measurable Residual Disease in AML

from Blood Cancer Talks · host Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

2021 European LeukemiaNET MRD Working Party Consensus Guidelines: https://pubmed.ncbi.nlm.nih.gov/34724563/Pre-MEASURE Study ASCO 2022: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7006

Episode metadata supplied by the publisher feed · Published Aug 24, 2022

Embed this episode

Attribution link and audio player

What this episode covers

In this episode, we discuss the techniques to assess measurable residual disease (MRD) in AML, clinical implications of MRD results, and future directions on MRD-guided patient management.

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Episode 4. Measurable Residual Disease in AML

0:00 1:02:50

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Blood Cancer Talks?

This episode is 1 hour and 2 minutes long.

When was this Blood Cancer Talks episode published?

This episode was published on August 24, 2022.

Can I download this Blood Cancer Talks episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!